Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,137
Out of 5,090 analysts
36
Total ratings
35%
Success rate
-24.11%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $48.92 | -14.15% | 1 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Hold | $30 → $13 | $12.93 | +0.54% | 3 | Oct 14, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $489.31 | -11.71% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $5.05 | +58.42% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.66 | +126.65% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $73.64 | -55.19% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.22 | +2,195.08% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $21.81 | +23.80% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.35 | +197.87% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.12 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.74 | +568.45% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $4.17 | +359,612.23% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.22 | +492.42% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.91 | +17.02% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $329.89 | -33.31% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $181.30 | +70.99% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $121.22 | -34.00% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $48.92
Upside: -14.15%
Astria Therapeutics
Oct 14, 2025
Downgrades: Hold
Price Target: $30 → $13
Current: $12.93
Upside: +0.54%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $489.31
Upside: -11.71%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $5.05
Upside: +58.42%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.66
Upside: +126.65%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $73.64
Upside: -55.19%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.22
Upside: +2,195.08%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $21.81
Upside: +23.80%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.35
Upside: +197.87%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.12
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.74
Upside: +568.45%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $4.17
Upside: +359,612.23%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $4.22
Upside: +492.42%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $29.91
Upside: +17.02%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $329.89
Upside: -33.31%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $181.30
Upside: +70.99%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $121.22
Upside: -34.00%